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Xenotransplantation is a potential solution to the 
current donor shortage for solid organ transplanta-
tion. The transmission of infectious agents from donor 
organs or bone marrow to the recipient is a well-rec-
ognized phenomenon following allotransplantation. 
Thus the prospect of xenotransplantation raises the 
issue of xenozoonoses-i.e., the transmission of animal 
infections to the human host. Anticipating an increas-
ing number of baboon to human transplants, 31 adult 
male baboons (Papio cynocephalus) from a single 
colony in the United States were screened for the pres-
ence of antibody to microbial agents (principally viral) 
that may pose a significant risk of infection. Antibody 
to simian cytomegalovirus, simian agent 8 and Ep-
stein-Barr virus, was found in 97% of animals tested. 
Antibody to simian retroviruses and Toxoplasma gon-
dii was found in 30% and 32% respectively. Discordant 
results were found when paired samples were exam-
ined by two primate laboratories. This was particu-
larly noted when methodologies were based on cross-
reaction with human viral antigens. These results 
highlight the need to develop specific antibody tests 
against the species used for xenotransplantation. 
Allotransplantation is an effective treatment for a variety 
of end-stage organ disorders. The number of people who can 
benefit from these procedures continues to grow as surgical 
techniques are refined and immunosuppressive regimens be-
come more specific and efficient. A shortage of appropriate 
donors prompts the need to explore other donor sources. Xe-
notransplantation offers a potential solution to the current 
donor shortage for solid organ transplantation. 
Infectious complications are a major cause of morbidity 
and mortality following allotransplantation (1,2). Sources of 
infection include the recipient's normal flora or latently har-
bored organisms, environmental contamination, and organ-
isms carried within the donor organ. Accordingly, a concern 
exists for inadvertent transmission of animal infections or 
xenozoonoses to the new human host during xenotransplan-
tation. 
The purpose of this screening study was to determine the 
seroprevalence of specific microbial agents in a baboon popu-
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lation that may pose a significant threat after xenotransplan-
tation. The decision to screen for an organism was based 
on recognition that the analogous human organism causes 
donor-associated disease (1,2), or that zoonotic transmission 
between primates and humans has been shown (3). 
METHODS 
Thirty-one adult male baboons ranging in age between six and 16 
years were screened serologically. All animals were raised at the 
Southwest Foundation for Biomedical Research in San Antonio, TX. 
The animals were housed in a six-acre corral containing approxi-
mately 450 baboons. Wild baboons have not been introduced into this 
colony for over ten years. Routine care included daily observation for 
signs of illness and tuberculin skin testing of animals and human 
care givers every six months. 
Toxoplasma gondii serology was performed by Sabin-Feldman dye 
test at The Palo Alto Medical Foundation, Research Institute, Palo 
Alto, CA. Paired serum samples were sent for herpesvirus and ret-
rovirus studies to two independent primate laboratories; Viral Ref-
erence Laboratory, Inc. (VRL), * San Antonio, TX and Microbiological 
Associates, Inc. (MA), Rockville, MD (Table 1). When available tests 
were specifically directed against the simian virus of interest (4, 5). 
If not available, laboratories relied on the crossreactivity of a test 
directed against the corresponding human virus. Positive and nega-
tive serum controls were performed with each test. In addition to 
serologic studies, plasma from 26 animals was inoculated by one 
laboratory (MA) into duplicate flasks of Raji cells to culture for sim-
ian AIDS retrovirus (SRV). Cultures were fed two times a week for 
two weeks and observed for typical syncytium formation. Suspect 
samples were incubated an additional seven days. 
RESULTS 
Serologic tests on 30 of 31 animals were positive for cyto-
megalovirus, Epstein-Barr virus, and simian agent 8 (SA8). 
No single animal was seronegative for more than one herpes-
virus. Discordant results (positive at one laboratory while 
negative at the other) were found for CMV (six animals) and 
SA8 (seven animals). Twenty-five discordant results were 
obtained for EBV serology. 
Antibody to SIV was not detected by either laboratory in 
any animal. Antibody against simian T lymphotropic virus 
type 1 (STLV-1) was found in eight animals. SRV antibody 
was present in two animals; cultures were negative. All ani-
* Abbreviations: EBNA, Epstein-Barr nuclear antigen; HTLV-l, 
human T lymphotropic virus type 1; MA, Microbiological Associates; 
SA8, simian agent 8; SIV, simian immunodeficiency virus; SRV, sim-
ian retrovirus; STLV-1, simian T lymphotropic virus type 1; VRL, 
Viral Reference Laboratory. 
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TABLE 1. Results of viral studies performed on paired samples from 31 adult male baboons at two primate reference 
laboratories 
Microbiological Viral Reference Laboratory, Total 
Virus 
Associates, Inc. (MA) Inc. (VRL) Positive 
Method (human or No. positive/ Method (human or from either No. positive/ laboratory primate antigen) No. performed primate antigen) No. performed (%) 
Cytomegalovirus ELISA a-Whittaker 19/25 DIA-VRL 30/31 97% 
Bioproducts (human) (primate) 
Epstein Barr ELISA-Whittaker 1126 IFA-Gull 30/31 97% 
virus Bioproducts (EBNA) Laboratory (VCA) 
(human) (human) 
Simian agent-8 IFA-MA (primate) 18/26 DIA-VRL 30/31 97% 
Simian IFA-MA (primate) 0/26 
(primate) 
DIA-VRL 0/31 0 
imm unodeficiency 
virus 
(primate) 
Simian ELISA-Coulter 5/26 DIA-VRL 5/31 24% 
T lymphotropic Immunology (primate) 
virus Laboratory (human) 
Simian AIDS IFA-MA (primate) 1126 DIA-VRL 1/31 6% 
retrovirus (primate) 
Hepatitis B virus ELISA-Diagnostic 1126 ELISA-Abbott 0/31 3% 
Assay Service Laboratory 
(human) (human) 
Hepatitis A virus ELISA-Organon 2/26 ELISA-Abbott 3/31 10% 
Teknika (human) Laboratory 
(human) 
Foamy virus IFA-MA (primate) 16/23 DIA-VRL 30/31 97% 
(primate) 
Lymphocytic IFA-MA (mouse) 0/26 DIA-VRL 0/31 0 
choriomeningitis (mouse) 
virus 
Simian Not performed DIA-VRL 0/31 0 
hemorrhagic fever (primate) 
virus 
Monkey pox virus Not performed DIA-VRL 0/31 0 
(primate) 
Measles ELISA-Sigma 12/26 DIA-VRL 23/31 74% 
Chemical Co. (human) 
(human) 
Marburg virus Not performed DIA-Center for 0/31 19% 
Disease Control 
a ELISA: enzyme-linked immunosorbent assay; DIA: dot-immunobinding assay; EBNA, Epstein Barr virus nuclear antigen; VCA, Epstein 
Barr virus viral capsid antigen; IFA, indirect immunofluorescence assay. 
mals except one were positive for foamy virus. Five discor-
dant results were found for STLV. 
Antibody to T gondii was found in ten animals. Antibody to 
hepatitis B surface antigen was found in a single animal and 
hepatitis A virus IgG was present in three baboons. No ani-
mal was positive for lymphocytic choriomeningitis virus, sim-
ian hemorrhagic fever virus, Marburg virus or monkey pox 
virus. 
DISCUSSION 
The decision to screen for specific microbial organisms was 
based on (1) the knowledge that certain organisms are asso-
ciated with donor transmitted infections after allotransplan-
tation, (2) the concern that some endemic primate viruses are 
potentially fatal to humans, and (3) the availability of tech-
niques to differentiate species specific viruses in order 
to document transmission of infection from primates to 
humans. 
Members of the herpesvirus family such as CMV and EBV 
are well recognized as donor transmitted infections after al-
lotransplantation (1, 6, 7). Antibody to these viruses were 
ubiquitous in our population of adult male baboons. A smaller 
study of ten wild baboons showed similar results for CMV but 
not positive antibody against EBV (8). In the current study, 
EBV results were highly discordant between laboratories 
both of which employed studies relying on crossreactivity of 
the baboon EBV-like organism, herpesvirus papio with hu-
man antibody. MA utilized a commercial ELISA directed 
against human EBV nuclear antigen (Whittaker Bioprod-
ucts), while VRL employed IFA directed against human EBV 
viral capsid antigen (Gull Laboratories). The discordant re-
sults may be explained by data from a previous study sug-
gesting that baboon VCA has more crossreactivity with the 
human VCA than the EBNA (9). Also the recent sequencing 
of herpesvirus papio EBNA-2 shows significant divergence 
from human EBV EBNA-2 protein (10). 
SA8 was found in 97% of animals. This virus is analogous 
to human herpes simplex virus causing self-limited, recur-
rent oral and genital lesions in primates. Acquisition is simi-
lar to that of herpes simplex in humans; increasing preva-
lence is found in primates with increasing age, particularly 
after sexual maturation (11). Serologic studies have been 
developed that distinguish SA8 from herpes simplex and H. 
simiae (B virus) (12, 13). While herpes simplex virus is not 
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considered a typical donor-associated pathogen, finding SAB 
in a recipient would demonstrate transmission across species 
lines. Likewise, SAB is similar to B virus, which is endemic in 
Macaca spp. and causes fatal disease in humans (3). SAB has 
not been demonstrated to be transmitted from a baboon to a 
human. A recent report of positive B virus in baboons used a 
nonspecific assay directed against human herpes simplex 
that cannot distinguish the various viral species (14). The 
positive results were therefore likely due to crossreactivity 
with SAB rather than with B virus. 
Retroviruses can also be transmitted by organ transplan-
tation (15). STLV-1, analogous to human T lymphotropic vi-
rus type 1 (HTLV-1) is found in as many as 40% of baboon 
populations studied (16). Because HTLV-1 has been associ-
ated with some forms of human T cell leukemias and an 
increased prevalence oflymphomas in macaque species (17) 
the presence of HTLV or STLV in potential xenograft donors 
is of importance. SRV has likewise been found in baboon 
populations in association with lymphomas (18). While sim-
ian immunodeficiency virus (SIV) analogous to human im-
munodeficiency virus type 2, is rare in baboon populations its 
detection would arouse great concern. While not included in 
this study, endogenous type C retroviruses are found in all 
baboons (18) and they or their genomic material represent an 
unknown infectious potential. 
Foamy virus is a spumavirus-type retrovirus which has not 
been clearly identified as a cause of disease (19). It is uncom-
mon in humans but highly prevalent in nonhuman primate 
species. Its presence in a recipient could be used to document 
transmission of a virus between species from xenotransplan-
tation. 
Hepatitis B antibody was found in one animal. Anti-Hhsag 
has been noted in several other serologic studies of wild and 
captive baboons (20, 21). While it is widely believed that 
baboons and many other nonhuman primates are not suscep-
tible to infection with hepatitis B virus (22) these serologic 
findings should be verified with current molecular tech-
niques. 
Evidence of infection with T gondii was found in 32% of the 
baboon population studied. Antibody was detected in 16 of 
100 wild baboons studied in South Mrica (23). This parasite 
has been transmitted after solid organ allotransplantation 
(1). While heart graft recipients are at highest risk, liver and 
renal transplant recipients can also be infected from a sero-
positive donor. The risk of transmission of T gondii from an 
animal organ would be expected to be the similar to the risk 
after allotransplantation. 
Serologic criteria for exclusion of an animal from a donor 
pool was used in our early xenotransplant experiments (24) 
to help limit the transmission of potential pathogens to the 
human transplant recipients. Animals with evidence of anti-
body against retroviruses other than foamy virus were ex-
cluded. Toxoplasma-positive animals were also excluded from 
the donor pool to avoid the additional need of prophylaxis 
with toxic chemotherapeutic agents. Foamy viruses have not 
been demonstrated to be pathogenic and serologic evidence of 
antibody to foamy virus was not used as an exclusionary 
factor for these early trials. Herpesviruses were ubiquitous in 
our population. CMV and EBV are generally considered to be 
species-specific (25). Although not a definite risk, there is 
potential for disease in the new host or reactivation within 
the xenograft itself. Antiviral agents do have activity against 
primate herpesviruses and may prove useful in prophylactic 
or treatment strategies (26). 
In summary, 30% of the adult animals tested had antibody 
against retroviruses and 32% against Toxoplasma. A total of 
16 or 52% were disqualified as potential donors based on 
serological screening. Reliance on crossreactivity with hu-
man antibody tests may have led to variable results between 
laboratories. It will be important to develop sensitive, easy-
to-perform assays directed against the organisms of a species 
chosen as a xenotransplant donor. Consideration has been 
given to raising primates in specific pathogen-free environ-
ments (3}-however, this would be logistically difficult and 
necessitate five to ten years because of the primate matura-
tion period. Furthermore, neither our screening methods nor 
the development of specific pathogen-free animals would ad-
dress the possibility of transmitting an as-yet-unrecognized 
primate organism to a naive human host (3). Follow-up sur-
veillance cultures along with serologic evaluation of the hu-
man recipients ofxenografts will be necessary to more accu-
rately define the risk of xenozoonoses. 
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